 CAMBRIDGE, Mass., Oct. 28, 2021 GLOBE NEWSWIRE -- Intellia Therapeutics, Inc. NASDAQ:NTLA, a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPRCas9 technology both in vivo and ex vivo, will present its third quarter 2021 financial results and operational highlights in a conference call on November 4, 2021 at 8 a.m. ET. 